Heterocyclic amines, cytochrome P4501A2, and N-acetyltransferase: Issues involved in incorporating putative genetic susceptibility markers into epidemiological studies

被引:11
作者
Sinha, R [1 ]
Caporaso, N [1 ]
机构
[1] NCI,DIV CANC EPIDEMIOL & GENET,NIH,ROCKVILLE,MD 20892
关键词
heterocyclic amines; cytochrome P4501A2; N-acetyltransferase MelQx; genotype; phenotype; inducible enzymes;
D O I
10.1016/S1047-2797(97)00027-6
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PURPOSE: Heterocyclic amines (HCAs), which are found mainly in well-cooked meat, require metabolic activation to function as mutagens and animal carcinogens. Enzymes such as cytochrome P4501A2 (CYP1A2) and N-acetyltransferase (NAT2) perform this task and are subject to interindividual variation. The source of this variation may be genetic, as in the case of NAT2, or both genetic and environmental as with CYP1A2. The present study examined the effect of HCAs on the NAT2 and CYP1A2 phenotypes in 33 males and 33 females. METHODS: The subjects consumed a low HCA-containing dirt for 1 week followed by a high HCA diet for the subsequent week. The subjects were phenotyped for CYP1A2 and NAT2 at the time of entry into the study (free-living), 1 week later (end of low-HCA or low-induction diet) and 2 weeks later (end of high-HCA or high-induction diet). RESULTS: Consistent with genetic sources oi variability, NAT2 showed little effect of a high-HCA diet and exhibited high intraindividual correlation. CYP1A2, in contrast, was induced by a high-HCA diet and exhibited a more modest intraindividual correlation. CONCLUSIONS: Incorporating putative genetic susceptibility makers in population studies requires consideration of issues of induction and inhibition of metabolizing enzymes, and effects of covariates. Published by Elsevier Science Inc.
引用
收藏
页码:350 / 356
页数:7
相关论文
共 30 条
[1]  
BOOBIS AR, 1994, CANCER RES, V54, P89
[2]   DETERMINATION OF CYP1A2 AND NAT2 PHENOTYPES IN HUMAN-POPULATIONS BY ANALYSIS OF CAFFEINE URINARY METABOLITES [J].
BUTLER, MA ;
LANG, NP ;
YOUNG, JF ;
CAPORASO, NE ;
VINEIS, P ;
HAYES, RB ;
TEITEL, CH ;
MASSENGILL, JP ;
LAWSEN, MF ;
KADLUBAR, FF .
PHARMACOGENETICS, 1992, 2 (03) :116-127
[3]   RELEVANCE OF METABOLIC POLYMORPHISMS TO HUMAN CARCINOGENESIS - EVALUATION OF EPIDEMIOLOGIC EVIDENCE [J].
CAPORASO, N ;
LANDI, MT ;
VINEIS, P .
PHARMACOGENETICS, 1991, 1 (01) :4-19
[4]  
CONNEY AH, 1982, CANCER RES, V42, P4875
[5]  
CONNEY AH, 1976, CLIN PHARMACOL THER, V20, P633
[6]   METABOLIC POLYMORPHISMS [J].
DALY, AK ;
CHOLERTON, S ;
GREGORY, W ;
IDLE, JR .
PHARMACOLOGY & THERAPEUTICS, 1993, 57 (2-3) :129-160
[7]   HEPATOCARCINOGENIC HETEROCYCLIC AROMATIC-AMINES THAT INDUCE CYTOCHROME-P-448 ISOZYMES, MAINLY CYTOCHROME-P-448H (P-450IA2), RESPONSIBLE FOR MUTAGENIC ACTIVATION OF THE CARCINOGENS IN RAT-LIVER [J].
DEGAWA, M ;
TANIMURA, S ;
AGATSUMA, T ;
HASHIMOTO, Y .
CARCINOGENESIS, 1989, 10 (06) :1119-1122
[8]  
DELEO JM, 1993, RECEIVER OPERATING C
[9]   Genetic metabolic polymorphisms and the risk of cancer: A review of the literature [J].
dErrico, A ;
Taioli, E ;
Chen, X ;
Vineis, P .
BIOMARKERS, 1996, 1 (03) :149-173
[10]   A FAMILY AND POPULATION STUDY OF THE GENETIC-POLYMORPHISM OF DEBRISOQUINE OXIDATION IN A WHITE BRITISH-POPULATION [J].
EVANS, DAP ;
MAHGOUB, A ;
SLOAN, TP ;
IDLE, JR ;
SMITH, RL .
JOURNAL OF MEDICAL GENETICS, 1980, 17 (02) :102-105